Novo Nordisk Submits MAA for Oral Semaglutide

Novo Nordisk has announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue tablet.

To be used as a treatment of adults with Type 2 diabetes, this once-daily oral formulation utilises Emisphere Technologies’ proprietary Eligen® SNAC Carrier Technology.

Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.

Company White Papers

Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC

riginally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin...

Make an enquiry

Your email address *

First name*

Last name*

Company*

Job title*

Job Function

Country*

Phone*

Message*

Thank you for submitting the form. Your enquiry will be submitted to the company.

Novo Nordisk Submits MAA for Oral Semaglutide

Company White Papers

Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC

Make an enquiry

Clinical Trials Arena Pipeline Moves

Clinical Trials Arena Weekly Roundup

Pharma Technology Focus Magazine

THANK YOU